CL2018002793A1 - Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de control - Google Patents
Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de controlInfo
- Publication number
- CL2018002793A1 CL2018002793A1 CL2018002793A CL2018002793A CL2018002793A1 CL 2018002793 A1 CL2018002793 A1 CL 2018002793A1 CL 2018002793 A CL2018002793 A CL 2018002793A CL 2018002793 A CL2018002793 A CL 2018002793A CL 2018002793 A1 CL2018002793 A1 CL 2018002793A1
- Authority
- CL
- Chile
- Prior art keywords
- control point
- cancer therapy
- point inhibitor
- oncolytic virus
- virus combined
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA EN LA CUAL UN INHIBIDOR DE PUNTO DE CONTROL SE COMBINA CON UN VIRUS ONCOLÍTICO Y AL USO DE DICHA COMBINACIÓN PARA EL TRATAMIENTO DE CÁNCER.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16163555 | 2016-04-01 | ||
EP16020193.5A EP3225253A1 (en) | 2016-04-01 | 2016-05-27 | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018002793A1 true CL2018002793A1 (es) | 2019-02-01 |
Family
ID=55650316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018002793A CL2018002793A1 (es) | 2016-04-01 | 2018-10-01 | Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de control |
Country Status (16)
Country | Link |
---|---|
US (2) | US11027013B2 (es) |
EP (1) | EP3225253A1 (es) |
JP (1) | JP6689400B2 (es) |
KR (1) | KR102195055B1 (es) |
CN (1) | CN109069601B (es) |
AU (1) | AU2017242089B2 (es) |
BR (1) | BR112018069927A2 (es) |
CA (1) | CA3019634A1 (es) |
CL (1) | CL2018002793A1 (es) |
EA (1) | EA037354B1 (es) |
IL (1) | IL261554B (es) |
LT (1) | LT3436058T (es) |
MX (1) | MX2018010709A (es) |
SG (1) | SG11201807977XA (es) |
WO (1) | WO2017167626A1 (es) |
ZA (1) | ZA201805548B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3056392A1 (en) * | 2017-03-15 | 2018-09-20 | Amgen Inc. | Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer |
CN109022616B (zh) * | 2018-07-25 | 2021-11-12 | 广州烨善生物科技有限公司 | 一种检测溶瘤病毒的探针及其应用 |
EP3657172A1 (en) | 2018-11-22 | 2020-05-27 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Method for predicting the clinical response of oncolytic parvovirus h1 (h-1pv) treatment in a patient suspected of suffering from cancer by measuring the expression levels of laminins and/or galectins as biomarkers in a patient´s sample |
MX2021009189A (es) * | 2019-02-01 | 2021-11-12 | Glaxosmithkline Ip Dev Ltd | Belantamab mafodotin en combinación con pembrolizumab para el tratamiento del cáncer. |
JP2022522479A (ja) * | 2019-02-28 | 2022-04-19 | シャタック ラボ,インコーポレイテッド | 併用療法 |
CN111154806A (zh) * | 2020-01-08 | 2020-05-15 | 深圳普菲科生命科技有限公司 | 一种嵌合外源超级细胞因子的溶瘤病毒载体系统及其在药物中的应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
US7179456B2 (en) * | 2003-04-30 | 2007-02-20 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Use of parvovirus for brain tumor therapy |
SI2439273T1 (sl) | 2005-05-09 | 2019-05-31 | Ono Pharmaceutical Co., Ltd. | Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki |
KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 pd-1에 대한 항체 |
EP2082745B1 (en) | 2007-12-28 | 2012-12-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Cancer therapy with a parvovirus combined with chemotherapy |
WO2009101611A1 (en) | 2008-02-11 | 2009-08-20 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
UA109108C2 (uk) | 2008-12-09 | 2015-07-27 | Дженентек, Інк. | Антитіло до pd-l1 та його застосування для посилення функції t-клітин |
EP2266588A1 (en) * | 2009-06-04 | 2010-12-29 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Method for cancer therapy based on co-administration of a parovirus and a cytokine |
EP2266587A1 (en) * | 2009-06-04 | 2010-12-29 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Oncolytic virotherapy for prevention of tumor recurrence |
EP2366398A1 (en) | 2010-03-17 | 2011-09-21 | Deutsches Krebsforschungszentrum | Cancer therapy with a parvovirus combined with an HDAC inhibitor |
EP2397542A1 (en) | 2010-06-17 | 2011-12-21 | Deutsches Krebsforschungszentrum | Modified parvovirus having enhanced anti-tumour efficacy |
EP2404609A1 (en) * | 2010-07-07 | 2012-01-11 | Deutsches Krebsforschungszentrum | Use of parvovirus for eliminating cancer stem cells (CSCs) |
EP2535055A1 (en) * | 2011-06-15 | 2012-12-19 | Deutsches Krebsforschungszentrum | Oncolytic virotherapy for therapy of bone cancer |
US20130129678A1 (en) * | 2011-11-17 | 2013-05-23 | Zahari Raykov | Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer |
DK2785375T3 (da) | 2011-11-28 | 2020-10-12 | Merck Patent Gmbh | Anti-pd-l1-antistoffer og anvendelser deraf |
EP2829284A1 (en) * | 2013-07-22 | 2015-01-28 | Deutsches Krebsforschungszentrum | Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor |
CU24481B1 (es) | 2014-03-14 | 2020-03-04 | Immutep Sas | Moléculas de anticuerpo que se unen a lag-3 |
IL248507B (en) * | 2014-05-13 | 2022-07-01 | Bavarian Nordic As | Combined therapy for the treatment of cancer with a recombinant focovirus that expresses an antigen and an antagonist or agonist for an immune control molecule |
US10765710B2 (en) * | 2014-07-16 | 2020-09-08 | Institut Gustave-Roussy | Combination of oncolytic virus with immune checkpoint modulators |
EP3108892A1 (en) * | 2015-06-23 | 2016-12-28 | Deutsches Krebsforschungszentrum | Parvovirus formulation for treating tumors |
-
2016
- 2016-05-27 EP EP16020193.5A patent/EP3225253A1/en not_active Withdrawn
-
2017
- 2017-03-22 CA CA3019634A patent/CA3019634A1/en active Pending
- 2017-03-22 AU AU2017242089A patent/AU2017242089B2/en active Active
- 2017-03-22 JP JP2018550530A patent/JP6689400B2/ja active Active
- 2017-03-22 BR BR112018069927A patent/BR112018069927A2/pt not_active Application Discontinuation
- 2017-03-22 CN CN201780022557.7A patent/CN109069601B/zh active Active
- 2017-03-22 KR KR1020187031490A patent/KR102195055B1/ko active IP Right Grant
- 2017-03-22 WO PCT/EP2017/056886 patent/WO2017167626A1/en active Application Filing
- 2017-03-22 MX MX2018010709A patent/MX2018010709A/es unknown
- 2017-03-22 SG SG11201807977XA patent/SG11201807977XA/en unknown
- 2017-03-22 EA EA201891679A patent/EA037354B1/ru unknown
- 2017-03-22 LT LTEP17730376.5T patent/LT3436058T/lt unknown
-
2018
- 2018-08-20 ZA ZA201805548A patent/ZA201805548B/en unknown
- 2018-09-03 IL IL261554A patent/IL261554B/en unknown
- 2018-10-01 CL CL2018002793A patent/CL2018002793A1/es unknown
- 2018-10-01 US US16/148,257 patent/US11027013B2/en active Active
-
2021
- 2021-04-09 US US17/226,199 patent/US11964015B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
LT3436058T (lt) | 2020-02-10 |
US11027013B2 (en) | 2021-06-08 |
ZA201805548B (en) | 2019-11-27 |
US20210228714A1 (en) | 2021-07-29 |
JP6689400B2 (ja) | 2020-04-28 |
IL261554A (en) | 2018-10-31 |
KR20180127468A (ko) | 2018-11-28 |
MX2018010709A (es) | 2019-01-14 |
US11964015B2 (en) | 2024-04-23 |
AU2017242089A1 (en) | 2018-08-30 |
EA201891679A1 (ru) | 2019-04-30 |
IL261554B (en) | 2022-05-01 |
KR102195055B1 (ko) | 2020-12-24 |
BR112018069927A2 (pt) | 2019-02-05 |
EA037354B1 (ru) | 2021-03-17 |
WO2017167626A1 (en) | 2017-10-05 |
US20190117768A1 (en) | 2019-04-25 |
JP2019510769A (ja) | 2019-04-18 |
CA3019634A1 (en) | 2017-10-05 |
CN109069601B (zh) | 2022-05-10 |
NZ745264A (en) | 2020-10-30 |
AU2017242089B2 (en) | 2019-08-15 |
CN109069601A (zh) | 2018-12-21 |
EP3225253A1 (en) | 2017-10-04 |
SG11201807977XA (en) | 2018-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018002793A1 (es) | Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de control | |
CL2018002012A1 (es) | Derivados de maitansinoide, conjugados de los mismos y métodos de uso. | |
CL2017002050A1 (es) | Uso de plinabulina en combinación con inhibidores de punto de control inmunitario | |
CL2018001358A1 (es) | Composiciones que comprenden cepas bacterianas | |
DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
BR112019005908A2 (pt) | uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres | |
CO2017002170A2 (es) | Terapia de combinación para tratar un paramixovirus | |
CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
CL2018000978A1 (es) | Macrociclos peptídicos contra acinetobacter baumannii | |
CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
CL2017002422A1 (es) | Derivados de maitansinoide, conjugados de los mismos, y métodos de uso. | |
ECSP17073743A (es) | Moduladores de k-ras | |
MX2018008346A (es) | Terapia de combinación de virus oncológico e inhibidor de punto de control. | |
CL2016001609A1 (es) | Composiciones farmacéuticas que comprenden azd9291. | |
CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
BR112018011133A2 (pt) | alvos terapêuticos para a correção do gene humano de distrofina por edição de gene e métodos de uso | |
CL2015002891A1 (es) | Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales. | |
EP3148336A4 (en) | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer | |
CL2015002571A1 (es) | Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático. | |
BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
DOP2016000336A (es) | Derivados de isoindolina para uso en el tratamiento de una infeccion viral | |
CL2017001209A1 (es) | Inhibidor de cinasa aurora a |